Logo image
Risk-based guidelines: Redefining management of abnormal cervical cancer screening results
Journal article   Open access   Peer reviewed

Risk-based guidelines: Redefining management of abnormal cervical cancer screening results

Amy Wiser, Jeffrey D Quinlan and Pelin Batur
Cleveland Clinic journal of medicine, Vol.88(10), pp.556-560
10/01/2021
DOI: 10.3949/ccjm.88a.20193
PMID: 34598920
url
https://doi.org/10.3949/ccjm.88a.20193View
Published (Version of record) Open Access

Abstract

In making the 2019 guidelines for risk-based management of patients with abnormal cervical cancer screening tests and cancer precursors, the guidelines committee shifted from results-based to risk-based management recommendations, based on the patient's immediate and 5-year risks of grade 3 or higher cervical intraepithelial neoplasia (CIN 3+). The risk is determined by current and prior screening results (human papillomavirus infection, cytology testing) and the clinical history including age. An immediate 4% or higher risk of CIN 3+ was established as the dividing line between higher and lower risks, and the corresponding management recommendations. This article reviews the changes and their evidence base and discusses clinical implications of the revised guidelines.
Cervical Intraepithelial Neoplasia - diagnosis Early Detection of Cancer Female Humans Mass Screening Papillomaviridae Papillomavirus Infections - complications Papillomavirus Infections - diagnosis Uterine Cervical Neoplasms - diagnosis Vaginal Smears

Details

Metrics

Logo image